Amylyx Pharmaceuticals

Advancing AMX0114 for ALS: Updates from the LUMINA Phase 1 Study

Advancing AMX0114 for ALS: Updates from the LUMINA Phase 1 Study wayne.gonsalves Wed, 06/24/2026 - 05:59 Wed, 06/24/2026 - 06:00 /document/ENCALS-2026-LUMINA.pdf European Network to Cure ALS (ENCALS) 2026 Meeting AMX0114

Participant-Informed Design Considerations in Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia

Participant-Informed Design Considerations in Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia itsupport Tue, 06/16/2026 - 00:43 Tue, 06/16/2026 - 00:44 /document/ENDO-2026-LUCIDITY.pdf Endocrine Society’s Annual Meeting (ENDO 2026) Avexitide

Characterizing the Burden of Post-Bariatric Hypoglycemia in the United States

Characterizing the Burden of Post-Bariatric Hypoglycemia in the United States itsupport Tue, 06/16/2026 - 00:42 Tue, 06/16/2026 - 00:43 /document/ENDO-2026-burden-of-PBH.pdf Endocrine Society’s Annual Meeting (ENDO 2026) Avexitide

AMX0035 in Wolfram Syndrome: Program Progress and Emerging Insights

AMX0035 in Wolfram Syndrome: Program Progress and Emerging Insights itsupport Thu, 06/04/2026 - 03:58 Thu, 06/04/2026 - 06:52 /document/WSUK-2026-HELIOS-AMX0035.pdf Wolfram Syndrome UK’s International Researcher’s Symposium AMX0035

Phase 2 trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome

Phase 2 trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome itsupport Mon, 05/18/2026 - 00:39 Mon, 05/18/2026 - 00:40 https://www.jci.org/articles/view/198519 The Journal of Clinical Investigation AMX0035

Initial Safety Findings from the Phase 1 LUMINA Trial of AMX0114 in Amyotrophic Lateral Sclerosis

Initial Safety Findings from the Phase 1 LUMINA Trial of AMX0114 in Amyotrophic Lateral Sclerosis wayne.gonsalves Wed, 03/11/2026 - 10:36 Wed, 03/11/2026 - 10:44 /document/MDA-2026-LUMINA.pdf Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 AMX0114